Lynn Anne Bristol

Array ( [id] => 11357380 [patent_doc_number] => 09534023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-03 [patent_title] => 'Mutated immunoglobulin-binding protein' [patent_app_type] => utility [patent_app_number] => 14/845817 [patent_app_country] => US [patent_app_date] => 2015-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 10858 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14845817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10706878 [patent_doc_number] => 20160053025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-25 [patent_title] => 'ANTI-C-MET/ANTI-ANG2 BISPECIFIC ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/835376 [patent_app_country] => US [patent_app_date] => 2015-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 34345 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14835376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13051561 [patent_doc_number] => 10047162 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => Sequence dependent aggregation [patent_app_type] => utility [patent_app_number] => 14/832505 [patent_app_country] => US [patent_app_date] => 2015-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 5589 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14832505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13065481 [patent_doc_number] => 10053513 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-21 [patent_title] => Antibody Fc mutants with ablated effector functions [patent_app_type] => utility [patent_app_number] => 14/818864 [patent_app_country] => US [patent_app_date] => 2015-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 10544 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14818864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10685874 [patent_doc_number] => 20160032019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'Antibody constructs for CDH19 and CD3' [patent_app_type] => utility [patent_app_number] => 14/815861 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 44148 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14815861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16665127 [patent_doc_number] => 10934360 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-02 [patent_title] => Human monoclonal antibodies against EPHA4 and their use [patent_app_type] => utility [patent_app_number] => 15/329659 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 30329 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15329659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10712737 [patent_doc_number] => 20160058885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'Antibodies With Immune Effector Activity and that Internalize In Folate Receptor Alpha-positive Cells' [patent_app_type] => utility [patent_app_number] => 14/809887 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 14021 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14809887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10706851 [patent_doc_number] => 20160052999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-25 [patent_title] => 'FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF' [patent_app_type] => utility [patent_app_number] => 14/807951 [patent_app_country] => US [patent_app_date] => 2015-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 21374 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807951 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11647879 [patent_doc_number] => 20170143780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS' [patent_app_type] => utility [patent_app_number] => 15/325576 [patent_app_country] => US [patent_app_date] => 2015-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 19513 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15325576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971204 [patent_doc_number] => 20170275359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'ANTI-EPHRINB2 ANTIBODIES AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 14/800588 [patent_app_country] => US [patent_app_date] => 2015-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 45035 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14800588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10755998 [patent_doc_number] => 20160102151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-14 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS' [patent_app_type] => utility [patent_app_number] => 14/798312 [patent_app_country] => US [patent_app_date] => 2015-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 53037 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14798312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10421232 [patent_doc_number] => 20150306244 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'Anthracycline-Antibody Conjugates for Cancer Therapy' [patent_app_type] => utility [patent_app_number] => 14/793887 [patent_app_country] => US [patent_app_date] => 2015-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 19095 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14793887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12166159 [patent_doc_number] => 09884921 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-06 [patent_title] => 'Bispecific heterodimeric diabodies and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/751704 [patent_app_country] => US [patent_app_date] => 2015-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 54 [patent_no_of_words] => 48482 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14751704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10491258 [patent_doc_number] => 20150376279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-31 [patent_title] => 'CELL PENETRATING NUCLEOLYTIC ANTIBODY BASED CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 14/750683 [patent_app_country] => US [patent_app_date] => 2015-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 15172 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14750683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10489794 [patent_doc_number] => 20150374815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-31 [patent_title] => 'METHODS AND COMPOSITIONS FOR TREATMENT WITH SYNTHETIC NANOCARRIERS AND IMMUNE CHECKPOINT INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/751106 [patent_app_country] => US [patent_app_date] => 2015-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 21771 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14751106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11521691 [patent_doc_number] => 09605077 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-28 [patent_title] => 'Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers' [patent_app_type] => utility [patent_app_number] => 14/739701 [patent_app_country] => US [patent_app_date] => 2015-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 26750 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14739701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12509355 [patent_doc_number] => 10000570 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-19 [patent_title] => Antibody variants having modifications in the constant region [patent_app_type] => utility [patent_app_number] => 14/739768 [patent_app_country] => US [patent_app_date] => 2015-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 18 [patent_no_of_words] => 25364 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14739768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10483325 [patent_doc_number] => 20150368345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-24 [patent_title] => 'ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION' [patent_app_type] => utility [patent_app_number] => 14/739771 [patent_app_country] => US [patent_app_date] => 2015-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 26935 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14739771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12813322 [patent_doc_number] => 20180162944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => NOVEL ANTI-PD-L1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/580281 [patent_app_country] => US [patent_app_date] => 2015-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15580281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11822939 [patent_doc_number] => 20170211876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'METHOD FOR SELECTING ANTIBODIES WITH MODIFIED FCRN INTERACTION' [patent_app_type] => utility [patent_app_number] => 15/317324 [patent_app_country] => US [patent_app_date] => 2015-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 5415 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15317324 [rel_patent_id] =>[rel_patent_doc_number] =>)